Navigation Links
Leukemia patients remain in remission more than 2 years after engineered T cell therapy
Date:12/9/2012

ization and carries at least a 20 percent mortality risk -- and even then offers only a limited chance of cure for patients whose disease has not responded to other treatments.

Three abstracts about the new research will be presented during the ASH meeting. David Porter, MD, director of Blood and Marrow Transplantation in the Abramson Cancer Center, will give an oral presentation of Abstract #717 on Monday, Dec. 10, at 5 PM in the Thomas Murphy Ballroom 4, Level 5, Building B of the Georgia World Congress Center. Michael Kalos, PhD, director of the Translational and Correlative Studies Laboratory at Penn, will give an oral presentation on Abstract #756 on Monday, Dec. 10, at 5:45 PM in C208-C210, Level 2, Building C. Stephan Grupp, MD, PhD, director of Translational Research in the Center for Childhood Cancer Research at the Children's Hospital of Philadelphia, will present a poster of Abstract #2604 on Sunday, Dec. 9, at 6 PM in Hall B1-B2, Level 1, Building B.

The protocol for the new treatment involves removing patients' cells through an apheresis process similar to blood donation, and modifying them in Penn's cell and vaccine production facility. Scientists there reprogram the patients' T cells to target tumor cells through a gene modification technique using a HIV-derived lentivirus vector. The vector encodes an antibody-like protein, called a chimeric antigen receptor (CAR), which is expressed on the surface of the T cells and designed to bind to a protein called CD19.

The modified cells are then infused back into the patient's body following lymphodepleting chemotherapy. Once the T cells start expressing the CAR, they focus all of their killing activity on cells that express CD19, which includes CLL and ALL tumor cells, and normal B cells. All of the other cells in the patient that do not express CD19 are ignored by the modified T cells, which limits systemic side effects typically experienced during traditional therapies.'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
2. Chernobyl cleanup workers had significantly increased risk of leukemia
3. Gene discovery could improve treatment for acute myeloid leukemia
4. miR loss may power maligant transformation in chronic leukemia
5. Cancer scientists link ‘oncometabolite’ to onset of acute myeloid leukemia
6. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
7. Another muscular dystrophy mystery solved; MU scientists inch closer to a therapy for patients
8. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
9. Ray of hope for human Usher syndrome patients
10. Walking on marbles could be a thing of the past for arthritis patients
11. Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... own painful dismay, do belly flops. But did you ... primitive living frogs do, according to a new study1 ... in the US, and colleagues, looking at the evolution ... became proficient at jumping before they perfected landing. This ...
... July, 2010 (Vienna, Austria) -- Can HIV infection ever ... in infected persons was the topic of a high-level, ... of AIDS 2010, the biennial international conference of HIV ... a Cure: HIV Reservoirs and Strategies to Control Them," ...
... CO 2 emissions could have a significant impact on ... out in Australia. Baby fish may become easy meat ... to CO 2 fallout from human activity, an international ... experiments reported in the latest issue of the Proceedings ...
Cached Biology News:Primitive frogs do a belly flop 2Top scientists tackle the issue of HIV persistence 2Carbon emissions threaten fish populations 2Carbon emissions threaten fish populations 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... Pa. , July 30, 2015  Discovery ... that it has received the second $1.0M tranche ... Innovation Research (SBIR) grant valued at up to ... company,s aerosolized KL4 surfactant as a potential medical ... injury.  Discovery Labs was awarded an initial $1.0 ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... -- Sanofi, un leader mondial et ... le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription :  ... sommaire de l,interview :  - Résultats ... - Diabète - Praluent ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Bay, Wis. - MailFoundry , a provider of ... technology to combat new spam tactics known as ... attacks . , ,The company's chief executive said the new ... botnet spam attacks with no false positives and realtime detection ...
... Foundation for Taxpayer and Consumer Rights , a California ... on human embryonic stem cell patents held by the ... right direction, but don't go far enough to relinquish WARF's ... Public Patent Foundation , which have mounted a legal challenge ...
... Rockwell Automation's gift of $1 million to ... to support the advanced automation industry throughout southeastern Wisconsin, ... as a technology transfer niche, according to the executive ... said the UWM-Rockwell partnership will focus on three areas ...
Cached Biology Technology:WARF will ease stem cell licensing restrictions 2Rockwell's $1M gift to UWM will support advanced automation research 2Rockwell's $1M gift to UWM will support advanced automation research 3
... is the condition in which a lack ... and the various antioxidants. Oxidative stress ... of several diseases, including artherosclerosis, chronic inflammatory ... several antioxidant systems that are very important ...
...
... to the maintenance of appropriate levels ... important and diverse as those involved ... stress response, antigen presentation, modulation of ... cell cycle regulation, transcription, and signalling ...
... has been demonstrated that oxidative stress is ... cancer. Oxidative stress is the condition in ... physiological antioxidants exist leading to the damage ... to oxidative stress is through several antioxidant ...
Biology Products: